TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11345031

Group type: EXPERIMENTAL
Intervention: 50 mg Ukrain (5 mg every second day, 10 injections altogether)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 100 mg Ukrain (10 mg every second day, 10 injections altogether)
Number of subjects: 50
Study: 8627888

Group type: EXPERIMENTAL
Intervention: EGS-I (original device)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: EGS-II (revised over-the-wire system)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Overall intervention (both devices)
Number of subjects: 46
Study: 1597518

Group type: EXPERIMENTAL
Intervention: Anistreplase
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 3911832

Group type: EXPERIMENTAL
Intervention: Vitamin A (350,000 to 500,000 IU daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vitamin A (high dose)
Number of subjects: 100
Study: 30696254

Group type: EXPERIMENTAL
Intervention: Let's Talk About Children plus treatment as usual (n=20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Wait list control (treatment as usual) (n=19)
Number of subjects: 39
Study: 29931423

Group type: COMPARATOR
Intervention: Synbiotic supplementation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Probiotics supplementation
Number of subjects: 120
Study: 26860879

Group type: EXPERIMENTAL
Intervention: Brief Psychosocial Intervention (BPI) delivered over 5 weeks, including counseling sessions and telephone follow-up, in addition to usual service.
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual service (Control group)
Number of subjects: 65
Study: 24973002

Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin (bLf) oral spray and oral piroxicam
Number of subjects: 13

Group type: COMPARATOR
Intervention: Oral piroxicam
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin (bLf) oral spray and piroxicam
Number of subjects: 13
Study: 22124619

Group type: EXPERIMENTAL
Intervention: Community-based participatory research (CBPR) framework for tobacco cessation intervention
Number of subjects: 0
Study: 20643325

Group type: EXPERIMENTAL
Intervention: Foot and hand massage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 17978643

Group type: EXPERIMENTAL
Intervention: Lumbar support continuous passive motion (CPM) device
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Static lumbar support
Number of subjects: 31

Group type: COMPARATOR
Intervention: No lumbar support
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fixed lumbar support
Number of subjects: 31

Group type: COMPARATOR
Intervention: Lumbar support CPM
Number of subjects: 31
Study: 16321598

Group type: EXPERIMENTAL
Intervention: Foods enriched in long-chain n-3 fatty acids (1 g/day)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control foods (not enriched)
Number of subjects: 85
Study: 11923244

Group type: EXPERIMENTAL
Intervention: FITC‐dextran (nonpenetrating fluorescent probe)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Buffered saline (control)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low-viscosity solutions (eta = 2.7‐7.7 mPa/sec)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-viscosity gel (eta approximately equal 30,000 mPa/sec)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Method repeatability
Number of subjects: 15
Study: 9485066

Group type: EXPERIMENTAL
Intervention: SCA1 carriers (2 symptomatic, 2 asymptomatic)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SCA1 carriers
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group of 10 healthy volunteers
Number of subjects: 10
Study: 8553083

Group type: EXPERIMENTAL
Intervention: Paclitaxel (135 mg/m2) and high-dose 5-fluorouracil (1.5-2.0 g/m2) with folinic acid (500 mg/m2) administered for 6 weeks, with paclitaxel given on days 1 and 22.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Paclitaxel and weekly high-dose 5-FU/FA regimen
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Dose level 4 (500 mg/m2 FA, 2.0 g/m2 5-FU, and 175 mg/m2 paclitaxel)
Number of subjects: 46
Study: 2652842

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 76
Study: 1175145

Group type: EXPERIMENTAL
Intervention: Pleural drainage with the instillation of radioactive colloidal chromic phosphate (PD + 32P) for 72 hours
Number of subjects: 67

Group type: COMPARATOR
Intervention: Pleural drainage alone (PD) for 72 hours
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy
Number of subjects: 67
Study: 31296602

Group type: EXPERIMENTAL
Intervention: Lightning Process, a neurolinguistic programming intervention, details on dosage and duration not available.
Number of subjects: 0
Study: 28251152

Group type: EXPERIMENTAL
Intervention: MOSQ‐TSP
Number of subjects: 68

Group type: COMPARATOR
Intervention: CONV‐TSP
Number of subjects: 68
Study: 25988365

Group type: EXPERIMENTAL
Intervention: Comprehensive Behavioral Intervention for Tics (CBIT)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Psychoeducation and Supportive Therapy (PST)
Number of subjects: 240
Study: 23127204

Group type: EXPERIMENTAL
Intervention: Aqueous progesterone formulation (100 mg) administered by subcutaneous injection
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Aqueous progesterone formulation (25 mg and 50 mg) administered by subcutaneous injection once daily for 11 days
Number of subjects: 61

Group type: COMPARATOR
Intervention: Intramuscular reference oily product
Number of subjects: 61
Study: 21854290

Group type: EXPERIMENTAL
Intervention: 8 mg buprenorphine
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: 16 mg buprenorphine
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: 24 mg buprenorphine
Number of subjects: 516
Study: 19587078

Group type: EXPERIMENTAL
Intervention: Diagnostic questionnaire score indicating CTS diagnosis
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Management model based on questionnaire score
Number of subjects: 152

Group type: COMPARATOR
Intervention: Nerve conduction studies (NCS)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Carpal tunnel release surgery
Number of subjects: 152
Study: 17242854

Group type: EXPERIMENTAL
Intervention: Asthma Education Program (AEP); one-day workshop and two follow-up telephone calls.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Delayed Asthma Education Program (control group).
Number of subjects: 64
Study: 14665554

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) solution
Number of subjects: 40
Study: 11687764

Group type: EXPERIMENTAL
Intervention: Acute sodium bicarbonate ingestion (0.5 g x kg(‐1) body mass)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Chronic sodium bicarbonate ingestion (0.5 g x kg(‐1) body mass daily for six days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 8
Study: 9140693

Group type: EXPERIMENTAL
Intervention: Procainamide (bid formulation) 1000, 2000, or 4000 mg/d
Number of subjects: 99

Group type: COMPARATOR
Intervention: Procainamide (qid formulation)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Procainamide (bid formulation)
Number of subjects: 99
Study: 8314137

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 93

Group type: COMPARATOR
Intervention: Nontreated
Number of subjects: 93
Study: 3328284

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg x 2 for 4-8 weeks (up to 12 weeks for gastric ulcers)
Number of subjects: 647

Group type: COMPARATOR
Intervention: Sucralfate 1 g x 4 for 4-8 weeks (up to 12 weeks for gastric ulcers)
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 647

Group type: COMPARATOR
Intervention: Sucralfate
Number of subjects: 647
Study: 31770758

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (PTX)
Number of subjects: 104

Group type: COMPARATOR
Intervention: No parathyroidectomy (non-PTX)
Number of subjects: 104
Study: 27849419

Group type: EXPERIMENTAL
Intervention: Pulse dexamethasone (group D)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pulse cyclophosphamide (group C)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination (pulse group DCP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 30
Study: 27504739

Group type: EXPERIMENTAL
Intervention: Baseline methylglyoxal
Number of subjects: 1481

Group type: EXPERIMENTAL
Intervention: Change in methylglyoxal during 6 years of follow-up
Number of subjects: 1481
Study: 24997826

Group type: EXPERIMENTAL
Intervention: Piglitazone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study: 22238468

Group type: EXPERIMENTAL
Intervention: HIV-positive women
Number of subjects: 188

Group type: COMPARATOR
Intervention: HIV-negative women
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Women with cord P. falciparum infection
Number of subjects: 188
Study: 20863330

Group type: EXPERIMENTAL
Intervention: DHEA (50 mg/d)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 18038223

Group type: EXPERIMENTAL
Intervention: Abstinence condition (overnight smoking abstinence)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Satiated condition (participants smoked up to and during the session)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cognitive measures (e.g., rapid visual information processing task, cued Go/No-Go task)
Number of subjects: 26
Study: 16148558

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 60
Study: 11951074

Group type: EXPERIMENTAL
Intervention: Doxofylline 400 mg t.i.d.
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Theophylline 250 mg t.i.d. (active control)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Doxofylline 200 mg t.i.d.
Number of subjects: 346

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Theophylline 250 mg t.i.d.
Number of subjects: 346
Study: 10069631

Group type: EXPERIMENTAL
Intervention: Transumbilical cholecystectomy through 2 ports
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard laparoscopic cholecystectomy through 4 ports
Number of subjects: 90
Study: 7733026

Group type: EXPERIMENTAL
Intervention: Palmolein
Number of subjects: 21

Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 21
Study: 1790160

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 1134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1134
Study: 7021747

Group type: EXPERIMENTAL
Intervention: Stroke unit rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical unit rehabilitation
Number of subjects: 0
Study: 30878017

Group type: EXPERIMENTAL
Intervention: Patisiran, 0.3 mg/kg, via intravenous infusion once every 3 weeks for 18 months
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Patisiran
Number of subjects: 126
Study: 29630009

Group type: EXPERIMENTAL
Intervention: Healthy lifestyle package (antenatal behavior change intervention supported by smartphone application technology)
Number of subjects: 565

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 565
Study: 27876004

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg from recruitment until 36+0 weeks or delivery, whichever occurs sooner, in addition to standard high risk care (which includes aspirin 100 mg daily and calcium 1000-1500 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard high risk care (which includes aspirin 100 mg daily and calcium 1000-1500 mg daily)
Number of subjects: 0
Study: 23795582

Group type: EXPERIMENTAL
Intervention: Early surfactant (ES) treatment (200 mg/kg Curosurf® within 1 hour after birth)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Late selective (LS) treatment (200 mg/kg Curosurf® within the first 6 hours of life if needed)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Early surfactant (ES) treatment
Number of subjects: 159

Group type: COMPARATOR
Intervention: Late selective (LS) treatment
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Both ES and LS treatments
Number of subjects: 159
Study: 22649143

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 19296774

Group type: COMPARATOR
Intervention: Adaptive design trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adaptive sequence of trials
Number of subjects: 0
Study: 17190759

Group type: EXPERIMENTAL
Intervention: GLP-1 (9-36)amide (5 pmol/kg body wt/min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 6
Study: 16773435

Group type: EXPERIMENTAL
Intervention: Cigarette smoking for 40 years
Number of subjects: 89835

Group type: EXPERIMENTAL
Intervention: Cigarette smoking intensity of 40 cigarettes per day
Number of subjects: 89835

Group type: EXPERIMENTAL
Intervention: Cumulative exposure of 40 pack-years
Number of subjects: 89835

Group type: EXPERIMENTAL
Intervention: Latency of cigarette smoking for 40 years since commencement
Number of subjects: 89835

Group type: EXPERIMENTAL
Intervention: Smoking initiation before first full-term pregnancy (more than 5 years of smoking)
Number of subjects: 89835
Study: 12829148

Group type: EXPERIMENTAL
Intervention: Rigid immobilization (RI) devices
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no immobilization devices)
Number of subjects: 100
Study: 11054225

Group type: EXPERIMENTAL
Intervention: SCD Response Compression System
Number of subjects: 12

Group type: COMPARATOR
Intervention: SCD Sequel Compression System
Number of subjects: 12
Study: 9026570

Group type: EXPERIMENTAL
Intervention: High myopia group (42 patients)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: High myopia with retinal detachment surgery group (4 patients)
Number of subjects: 46
Study: 1326031

Group type: EXPERIMENTAL
Intervention: Imagery-only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imagery/relaxation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Audiotaped imagery
Number of subjects: 0
Study: 6340424

Group type: EXPERIMENTAL
Intervention: 30 ml cod liver oil (CLO) daily for 6 weeks
Number of subjects: 0
Study: 31631501

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 143

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 143
Study: 30076623

Group type: EXPERIMENTAL
Intervention: Fasted horses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fed horses
Number of subjects: 0
Study: 27530758

Group type: EXPERIMENTAL
Intervention: Functional training of the paretic upper limb combined with anodic transcranial stimulation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Functional training of the paretic upper limb combined with sham transcranial stimulation
Number of subjects: 34
Study: 25509734

Group type: EXPERIMENTAL
Intervention: Acupuncture at three lines of cervical Jiaji (EX-B 2), once a day for 10 days, two sessions total.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Jingfukang granules, one bag three times a day for 10 days, two sessions total.
Number of subjects: 300
Study: 23128491

Group type: EXPERIMENTAL
Intervention: cHerbst appliance
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (untreated Class II subjects)
Number of subjects: 40
Study: 20861632

Group type: EXPERIMENTAL
Intervention: liquid dentifrice, 1,100 ppm F, pH 4.5
Number of subjects: 1402

Group type: EXPERIMENTAL
Intervention: liquid dentifrice, 1,100 ppm F, pH 7.0
Number of subjects: 1402

Group type: EXPERIMENTAL
Intervention: liquid dentifrice, 550 ppm F, pH 4.5
Number of subjects: 1402

Group type: EXPERIMENTAL
Intervention: toothpaste, 1,100 ppm F, pH 7.0
Number of subjects: 1402
Study: 16983507

Group type: EXPERIMENTAL
Intervention: Carbamazepine (Treatment A)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (Treatment B)
Number of subjects: 36
Study: 16276165

Group type: EXPERIMENTAL
Intervention: Fenoldopam (n = 150) at 0.09 microg x kg x min
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo (n = 150)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Fenoldopam (n = 150)
Number of subjects: 300
Study: 11925375

Group type: EXPERIMENTAL
Intervention: Biphasic oral contraceptive (norethindrone 500 microg/ethinyl estradiol 35 microg for 10 days, followed by norethindrone 1000 microg/ethinyl estradiol 35 microg for 11 days)
Number of subjects: 1014

Group type: COMPARATOR
Intervention: Monophasic oral contraceptive (norethindrone acetate 1500 microg/ethinyl estradiol 30 microg daily)
Number of subjects: 1014
Study: 10190921

Group type: EXPERIMENTAL
Intervention: Prednisolone (2 mg/kg/d for 3 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 8871356

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 0
Study: 2406782

Group type: EXPERIMENTAL
Intervention: Relaxation response audiotape
Number of subjects: 45

Group type: COMPARATOR
Intervention: Contemporary instrumental music audiotape
Number of subjects: 45

Group type: COMPARATOR
Intervention: Blank audiotape
Number of subjects: 45
Study: 7022849

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (Medrol)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 65
Study: 30068285

Group type: EXPERIMENTAL
Intervention: Free triiodothyronine
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Thyroid peroxidase antibodies
Number of subjects: 486
Study: 28714733

Group type: EXPERIMENTAL
Intervention: pure-PTP jury type
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: mixed-PTP jury type
Number of subjects: 648

Group type: COMPARATOR
Intervention: no PTP exposure
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: PTP exposure
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: different PTP slants
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: deliberating with others who do not share similar biases
Number of subjects: 648
Study: 26016820

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) capsule containing 28 mg memantine extended release (ER) and 10 mg donepezil
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: FDC capsule taken while fasting
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: FDC contents sprinkled on applesauce while fasting
Number of subjects: 74

Group type: COMPARATOR
Intervention: Co-administered memantine ER and donepezil
Number of subjects: 74
Study: 25628196

Group type: EXPERIMENTAL
Intervention: Postural drainage, tapping and tracheal aspiration (Group 1)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Postural drainage, expiratory acceleration flow and tracheal aspiration (Group 2)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Both interventions (Group 1 and Group 2)
Number of subjects: 29
Study: 21996634

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention program (SPRING) including exercise classes, nutrition classes, and bathing, twice a week for 3 months
Number of subjects: 60
Study: 19512980

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 17200909

Group type: EXPERIMENTAL
Intervention: Group 4 (both)
Number of subjects: 32
Study: 15356304

Group type: COMPARATOR
Intervention: Environmental intervention tailored to each child's allergic sensitization and environmental risk factors, lasting one year, including education and remediation for exposure to allergens and environmental tobacco smoke.
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: Environmental intervention
Number of subjects: 937
Study: 11592358

Group type: EXPERIMENTAL
Intervention: Leflunomide (LEF) 20 mg/day, loading dose 100 mg x 3 days
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Leflunomide (LEF)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 235
Study: 9555919

Group type: EXPERIMENTAL
Intervention: Partial body weight support with treadmill locomotion (32% body weight supported) during comfortable walking, fast walking, and running for 6 weeks.
Number of subjects: 1

Group type: COMPARATOR
Intervention: Baseline measurements taken for 6 weeks (phase AI) and a 3-week period without treatment (phase AII).
Number of subjects: 1
Study: 7850536

Group type: EXPERIMENTAL
Intervention: Stereotactic breast biopsy with a 14-gauge needle
Number of subjects: 416

Group type: COMPARATOR
Intervention: Stereotactic breast biopsy followed by surgical biopsy
Number of subjects: 416
Study: 3138445

Group type: EXPERIMENTAL
Intervention: Cyclic total parenteral nutrition (infusion between 5 pm and 9 am)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard continuous total parenteral nutrition (infusion 24 hr/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cyclic total parenteral nutrition
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard continuous total parenteral nutrition
Number of subjects: 12
Study: 31752643

Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Closure (LAAC)
Number of subjects: 1114

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1114
Study: 28064113

Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex (dLPFC) at 2mA for 30 minutes, 10 sessions over 10 consecutive days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham stimulation (Control group)
Number of subjects: 24
Study: 25927522

Group type: EXPERIMENTAL
Intervention: Aseptic, purified, cryopreserved, infectious P. falciparum sporozoites (Sanaria® PfSPZ Challenge) administered intramuscularly (IM)
Number of subjects: 28
Study: 23306147

Group type: EXPERIMENTAL
Intervention: Transdermal rivastigmine
Number of subjects: 1078

Group type: COMPARATOR
Intervention: Oral rivastigmine
Number of subjects: 1078
Study: 22129897

Group type: EXPERIMENTAL
Intervention: Oral lipoceutical glutathione
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Transdermal glutathione
Number of subjects: 26